Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.